Themed collection Tuberculosis

The physicochemical properties of TB drugs are compared oral drugs and antibiotics, which support likely roles for transporters contributing to their efficacy.

Innovations in mycobacterial drug discovery to accelerate the identification of new drug candidates with confirmed targets and whole cell activity.

Antibody binding to trehalose mycolates, such as that shown, was evaluated in ELISA. Median responses with the serum of individuals with no known mycobacterial infection were low; some were very high, the majority from Welsh farmers older than 55.

Screening for inhibitors of Cyt-bd in Mycobacterium bovis BCG and Mycobacterium tuberculosis revealed thieno[3,2-d]pyrimidine (7) which through SAR efforts resulted in an improved analogue (19) of this scaffold.

The formation efficiency of hydride-induced Meisenheimer complexes of nitroaromatic compounds is consistent with their anti-TB activities exemplied by MDL860 and benzothiazol N-oxide (BTO) analogs.

P218 is a potent inhibitor of M. ulcerans DHFR (K_i 3.2 nM).

Mycobacterium tuberculosis isocitrate lyases (ICLs) form a covalent adduct with itaconate through their catalytic cysteine residue. These results reveal atomic details of itaconate inhibition and provide insights into the catalytic mechanism of ICLs.

Filamenting temperature sensitive protein Z (FtsZ) is an essential bacterial cell division protein and a promising target for the development of new antibacterial therapeutics.

Ethionamide (ETH) is a commercial drug, used as a second-line resource to neutralize Mycobacterium tuberculosis infections.

This study identifies analogues of the natural product meridianin D that display increased ability to inhibit and disperse Mycobacterium smegmatis biofilms.